Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × HER2 Negative Breast Cancer × Drug Therapy × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 70 Breast Neoplasms 30 Lung Neoplasms 22 Colorectal Neoplasms 22 Rectal Neoplasms 21 Neoplasms 18 Esophageal Squamous Cell Carcinoma 18 Neoplasm Metastasis 15 Head and Neck Neoplasms 15 Esophageal Neoplasms 15 Stomach Neoplasms 13 Squamous Cell Carcinoma of Head and Neck 12 Small Cell Lung Carcinoma 12 Pancreatic Neoplasms 12 Triple Negative Breast Neoplasms 11 Ovarian Neoplasms 11 Carcinoma, Squamous Cell 10 Nasopharyngeal Carcinoma 9 Colonic Neoplasms 8 Recurrence 7 Prostatic Neoplasms 7 Lymphoma, Large B-Cell, Diffuse 7 Lymphoma 7 Leukemia, Myeloid, Acute 7 Sarcoma 6 Melanoma 6 Lymphoma, Non-Hodgkin 6 Uterine Cervical Neoplasms 5 Fallopian Tube Neoplasms 5 Cholangiocarcinoma 5

Interventions

ribociclib 1 Tretinoin 1 Letrozole 1 Goserelin 1 Drug Therapy 1 Chemotherapy, Adjuvant 1 Anastrozole 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06731140 2025-11-17

Resilire

Fudan University

Phase 2 Recruiting

HER2 Negative Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡